Resistance Patterns of Urinary Tract Pathogens Isolated from Patients with Type 2 Diabetes Mellitus on Sodium Glucose Co-transporter 2 Inhibitors Admitted in a Tertiary Hospital in the Philippines:
A Single-Center Retrospective Cohort Study
DOI:
https://doi.org/10.15605/jafes.040.02.17Keywords:
diabetes, SGLT2 inhibitors, urinary tract infection, urine culture, resistanceAbstract
Background. Congruent with the increasing prevalence of diabetes, a growing armamentarium of anti-diabetes medications has been introduced. Among these are sodium glucose co-transporter-2 inhibitors (SGLT2i).
Objectives. SGLT2i use has been linked to an increased incidence of urogenital infections. The study aims to compare resistance patterns of urinary tract isolates among patients with diabetes who are on SGLT2i and not on SGLT2i.
Methodology. Single-center retrospective cohort study. A total of 464 patients (75 on SGLT2i, 389 not on SGLT2i) with DM type 2 and urinary tract infection were included. Urine culture results were compared.
Results. A similar pattern of urinary tract isolates was found between groups except for C. albicans being more common in the SGLT2i group. There was no significant association between the presence of resistant urinary tract pathogens and the use of SGLT2i. There was no statistically significant difference in resistance rates between groups, except for Imipenem (p = 0.015).
Conclusion. SGLT2i use per se does not play a pivotal role in mediating bacterial resistance in urinary tract pathogens among patients with DM type 2. We do not recommend for or against the use of specific antimicrobials based on SGLT2
inhibitor alone. Patient’s clinical profile along with urine culture test results remain key factors in patient management
Downloads
References
1. Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia. 2007;50(3):549-54. https://pubmed.ncbi.nlm.nih.gov/17187246 https://doi.org/10.1007/s00125-006-0570-3
2. De Leon EM, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis. 2002;2:1. https://pubmed.ncbi.nlm.nih.gov/11835694 https://pmc.ncbi.nlm.nih.gov/articles/PMC65518 https://doi.org/10.1186/1471-2334-2-1
3. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103(3):373-81. Phttps://pubmed.ncbi.nlm.nih.gov/24529566 https://doi.org/10.1016/j.diabres.2013.12.052
4. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://pubmed.ncbi.nlm.nih.gov/26378978 https://doi.org/10.1056/NEJMoa1504720
5. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. https://pubmed.ncbi.nlm.nih.gov/28605608 https://doi.org/10.1056/NEJMoa1611925
6. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. https://pubmed.ncbi.nlm.nih.gov/30415602 https://doi.org/10.1056/NEJMoa1812389
7. Vasilakou D, Karagiannis T, Athanasiadou E, et al. SGLT2 inhibitors for T2DM: A systematic review and meta-analysis. Ann Intern Med. 2013;159(4);262-74. https://pubmed.ncbi.nlm.nih.gov/24026259 https://doi.org/10.7326/0003-4819-159-4-201308200-00007
8. Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with SGLT2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes, Obes, Metab. 2017;19(3):348-55. https://pubmed.ncbi.nlm.nih.gov/27862830 https://doi.org/10.1111/dom.12825
9. Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB. SGLT2i and the risk of infections: A systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55(5):503-14. PMID: 29484489 https://doi.org/10.1007/s00592-018-1116-0
10. Gadzhanova S, Pratt N, Roughead E. Use of SGLT2i for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight Program. Diabetes Res Clin Pract. 2017;130:180-5. PMID: 28646701 https://doi.org/10.1016/j.diabres.2017.06.018
11. Dave CV, Schneeweiss, Kim D, Fralick M, Tong A, Patorno E. SGLT2 inhibitors and the risk of severe urinary tract infections: A population-based cohort study. Ann Intern Med. 2019;171(4): 248-56. https://pubmed.ncbi.nlm.nih.gov/31357213 https://pmc.ncbi.nlm.nih.gov/articles/PMC6989379 https://doi.org/10.7326/M18-3136
12. Caro MKC, Cunanan EC, Kho SA. Incidence and factors associated with genitourinary infections among Type 2 diabetes patients on SGLT2 inhibitors: A single retrospective cohort study. Diabetes Epidemiol Manag. 2022;7:100082. https://doi.org/10.1016/j.deman.2022.100082
13. Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet TJ, Hoepelman AI; Diabetes Women Asymptomatic Bacteriuria Utrecht Study Group. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care. 2000;23(12):1737-41. https://pubmed.ncbi.nlm.nih.gov/11128343 https://doi.org/10.2337/diacare.23.12.1737
14. Geerlings SE, Meiland R, van Lith EC, Brouwer EC, Gaastra W, Hoepelman AI. Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells: More in diabetic women than in control subjects. Diabetes Care. 2002;25(8):1405-9. https://pubmed.ncbi.nlm.nih.gov/12145242 https://doi.org/10.2337/diacare.25.8.1405
15. Geerlings SE, Brouwer EC, Van Kessel KC, Gaastra W, Stolk RP, Hoepelman AI. Cytokine secretion is impaired in women with diabetes mellitus. Eur J Clin Invest 2000;30(11):995–1001. https://pubmed.ncbi.nlm.nih.gov/11114962 https://doi.org/10.1046/j.1365-2362.2000.00745.x
16. Geerlings SE, Brouwer EC, Gaastra W, Verhoef J, Hoepelman AIM. Effect of glucose and pH on uropathogenic and non- uropathogenic Escherichia coli: Studies with urine from diabetic and non-diabetic individuals. J Med Microbiol. 1999;48(6):535-9. https://pubmed.ncbi.nlm.nih.gov/10359302 https://doi.org/10.1099/00222615-48-6-535
17. Geerlings SE, Stolk RP, Camps MJ, et al. Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Mellitus Women Asymptomatic Bacteriuria Utrecht Study Group. Diabetes Care. 2000;23(6):744–9. https://pubmed.ncbi.nlm.nih.gov/10840989 https://doi.org/10.2337/diacare.23.6.744
18. Kaku K, Chin R, Naito Y, et al. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: Interim analysis from a post-marketing surveillance study. Expert Opin Drug Saf. 2020;19(2):211-21. https://pubmed.ncbi.nlm.nih.gov/31769309 https://doi.org/10.1080/14740338.2020.1694659
19. Inagaki N, Nangaku M, Sakata Y, et al. Safety and efficacy of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, as monotherapy and in combination with antidiabetic agents in patients with type 2 diabetes mellitus - an interim analysis of post-marketing surveillance (SAPPHIRE). Jpn Pharmacol Ther. 2018;46(4):499–519.
20. Nicolle LE, Capuano G, Ways K, Usiskin K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 2012;28(7):1167–71. https://pubmed.ncbi.nlm.nih.gov/22548646 https://doi.org/10.1185/03007995.2012.689956
21. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28(7):1173-8. https://pubmed.ncbi.nlm.nih.gov/22632452 https://doi.org/10.1185/03007995.2012.697053
22. Wanner C, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(18):1801-2. https://pubmed.ncbi.nlm.nih.gov/27806236 https://doi.org/10.1056/NEJMc1611290
23. Han SJ, Ha KH, Lee N, Kim DJ. Effectiveness and safety of SGLT2 inhibitors compared with DPP4 inhibitors in older adults with T2DM: A nationwide population-based study. Diabetes Obes Metab. 2021;23(3):682-91. https://pubmed.ncbi.nlm.nih.gov/33236515 https://pmc.ncbi.nlm.nih.gov/articles/PMC7898287 https://doi.org/10.1111/dom.14261
24. Kande S, Patro S, Panighari A, Khora PK, Pattnaik D. Prevalence of uropathogens and their antimicrobial resistance pattern among adult diabetic patients. Indian J Public Health. 2021;65(3):280-6. https://pubmed.ncbi.nlm.nih.gov/34558491 https://doi.org/10.4103/ijph.IJPH_1413_20
25. Tanrıverdi M, Baştemir M, Demirbakan H, Ünalan A, Türkmen M, Tanrıverdi GO. BMC ENdocr Disord. 2023;23(1):211. https://pubmed.ncbi.nlm.nih.gov/37789335 https://pmc.ncbi.nlm.nih.gov/articles/PMC10548559 https://doi.org/10.1186/s12902-023-01464-6
26. Geerlings SE, Meiland R, van Lith EC, Brouwer EC, Gaastra W, Hoepelman AI. Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells: More in diabetic women than in control subjects. Diabetes Care. 2002;25(8):1405-9. https://pubmed.ncbi.nlm.nih.gov/12145242 https://doi.org/10.2337/diacare.25.8.1405
27. Hiyama Y, Sato T, Takahashi S, et al. Reduction of susceptibility to azoles and 5-fluorocytosine and growth acceleration in Candida albicans in glucosuria. Diagn Microbiol Infect Dis. 2022;102(1):115556. https://pubmed.ncbi.nlm.nih.gov/34678714 https://doi.org/10.1016/j.diagmicrobio.2021.115556
28. Inns T, Millership S, Teare L, Rice W, Reacher M. Service evaluation of selected risk factors for extended-spectrum beta-lactamase Escherichia coli urinary tract infections: A case-control study. J Hosp Infect. 2014;88(2):116-9. https://pubmed.ncbi.nlm.nih.gov/25146227 https://doi.org/10.1016/j.jhin.2014.07.009
29. Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004;23(3):163-7. https://pubmed.ncbi.nlm.nih.gov/14986159 https://doi.org/10.1007/s10096-003-1084-2
30. Wu YH, Chen PL, Hung YP, Ko WC. Risk factors and clinical impact of levofloxacin or cefazolin nonsusceptibility or ESBL production among uropathogens in adults with community-onset urinary tract infections. J Microbiol Immunol Infect. 2014;47(3):197-203. https://pubmed.ncbi.nlm.nih.gov/23063776 https://doi.org/10.1016/j.jmii.2012.09.001
31. Schechner V, Kotlovsky T, Kazma M, et al. Asymptomatic rectal carriage of blaKPC producing carbapenem-resistant Enterobacteriaceae: Who is prone to become clinically infected? Clin Microbiol Infect. 2013;19(5):451-6. https://pubmed.ncbi.nlm.nih.gov/22563800 https://doi.org/10.1111/j.1469-0691.2012.03888.x
32. Papadimitriou-Olivgeris M, Drougka E, Fligou F, et al. Risk factors for enterococcal infection and colonization by vancomycin-resistant enterococci in critically ill patients. Infection. 2014;42(6):1013–22. https://pubmed.ncbi.nlm.nih.gov/25143193 https://doi.org/10.1007/s15010-014-0678-1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Catheryn Rose Rudinas, Ceryl Cindy Tan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The full license text is available at: http://creativecommons.org/licenses/by-nc/3.0/legalcode.
To request permission to translate, reproduce, download, or use articles or images for commercial reuse or business purposes from the Journal of the ASEAN Federation of Endocrine Societies (JAFES), kindly complete the Permission Request for Use of Copyrighted Material Form and email jafes@asia.com or jafes.editor@gmail.com.
A written agreement will be issued to the requester once permission has been granted.
